Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors
- 22 July 2016
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 56 (2) , 298-307
Abstract
Patients with Cushing disease (CD) are at increased risk of venous thromboembolism (VTE). It was surmised, but not conclusively shown that the risk is related to plasma hypercoagulability secondary to the glucocorticoids effect. This study is aimed at detecting hypercoagulability in patients with CD. Case-control study of 48 CD patients and controls enrolled at two Italian clinics for whom we assessed the thrombin-forming-potential in the presence of optimal activation of protein C obtained by adding into the assay system its main endothelial activator, thrombomodulin. These experimental conditions mimic more closely than any other test the in vivo situation. We observed enhanced thrombin-generation in CD patients, as shown by the modification of thrombin-generation parameters [i.e., shortened lag-time and time-to-peak, increased thrombin peak and endogenous thrombin potential (ETP)]. Moreover, the ETP ratio (with/without thrombomodulin), recognized as an index of hypercoagulability, was increased in patients as compared to controls. We attempted to explain such hypercoagulability by measuring both procoagulant and anticoagulant factors, and some other non-coagulation parameters (i.e., neutrophil extracellular traps (NET), recently associated with the VTE risk and/or increased hypercoagulability. We showed that the hypercoagulability in patients with CD is associated with increased levels of factor VIII and NET-related variables. We detected plasma hypercoagulability in patients with CD and found experimental explanation for its occurrence. Whether this hypercoagulability can entirely explain the occurrence of VTE in patients with CD should be investigated by ad-hoc clinical trials. However, until these studies will be available the evidence supports the concept that patients with CD are candidates for antithrombotic prophylaxis.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro ((IG-15507))
This publication has 48 references indexed in Scilit:
- Plasma DNA is elevated in patients with deep vein thrombosisJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2013
- Circulating Nucleosomes and Neutrophil Activation as Risk Factors for Deep Vein ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivoJournal of Experimental Medicine, 2012
- The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndromeEuropean Journal of Endocrinology, 2011
- Mortality and morbidity in Cushing’s syndrome in New ZealandClinical Endocrinology, 2011
- Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4Blood, 2011
- Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretionCancer, 2011
- Extracellular DNA traps promote thrombosisProceedings of the National Academy of Sciences, 2010
- The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2008
- Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulationProceedings of the National Academy of Sciences, 2007